Descrizione

Cell therapies aims to introduce new, healthy cells into a patient’s body, to replace the diseased or missing ones. Manufacturing them involves collecting a specific set of cells from the blood, modifying them to produce a more vigorous attack on a patient’s cancer cells, and then reinjecting them into the patient. The global cell therapy biomanufacturing market is set to increase by US$ 4.4 miliardi da 2022 A 2028, che rappresenta un tasso di crescita annuale composto (CAGR) Di 8.8% durante il periodo di previsione.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2018-2021 e previsione a 2028 covering key market aspects like sales value for cell therapy biomanufacturing. The global cell therapy biomanufacturing market is segmented on the basis of application, e regione. On the basis of application, the global cell therapy biomanufacturing market has been segmented into bone repair, cancer, cardiovascular diseases, neurological disorders, skeletal muscle repair, altri. Tra questi, the skeletal muscle repair segment was accounted for the highest revenue generator in 2021. In termini di geografia, the global cell therapy biomanufacturing market has been segmented into Asia Pacific, Europa, Nord America, COSA (Medio Oriente e Africa), America Latina. North America is estimated to account for the largest share of the global cell therapy biomanufacturing market.

The global cell therapy biomanufacturing market is highly competitive. As of 2021, the major players in the global cell therapy biomanufacturing market were Bone Therapeutics S.A., Caladrius Biosciences Inc., Iovance Biotherapeutics Inc., Lonza Group AG, Merck KGaA, Novartis AG, Regen BioPharma Inc., Regeneus Ltd., The Bristol-Myers Squibb Company (BMS).

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the cell therapy biomanufacturing market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Applicazione: bone repair, cancer, cardiovascular diseases, neurological disorders, skeletal muscle repair, altri
Regione: Asia Pacifico, Europa, Nord America, COSA (Medio Oriente e Africa), America Latina
Anni considerati: la presente relazione copre il periodo 2018 A 2028

Principali vantaggi per gli stakeholder

– Get a comprehensive picture of the global cell therapy biomanufacturing market
– Individuare i settori in crescita e le tendenze per gli investimenti

Sommario

Parte 1. introduzione
– Ambito dello studio
– Periodo di studio
– Ambito geografico
– Metodologia di ricerca
Parte 2. Cell therapy biomanufacturing market overview
Parte 3. Market breakdown by application
– Bone repair
– Cancer
– Cardiovascular diseases
– Neurological disorders
– Skeletal muscle repair
– Altri
Parte 4. Market breakdown by region
– Asia Pacifico
– Europa
– Nord America
– COSA (Medio Oriente e Africa)
– America Latina
Parte 5. Aziende chiave
– Bone Therapeutics S.A.
– Caladrius Biosciences, Inc.
– Iovance Biotherapeutics, Inc.
– Lonza Group AG
– Merck KGaA
– Novartis AG
– Regen BioPharma, Inc.
– Regeneus Ltd.
– The Bristol-Myers Squibb Company (BMS)
Informazioni su StrategyHelix
Disclaimer